Brought to you by 
Santarus gains anti-VLA-1 antibody in Covella acquisition
21 Sep 2010
Executive Summary
In the second of two new deals it penned on the same day to bulk up on biologics, specialty pharmaco Santarus Inc. has acquired private biotech start-up Covella Pharmaceuticals Inc. for $1.8mm plus an undisclosed amount in clinical and regulatory milestones.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Santarus gains anti-VLA-1 antibody in Covella acquisition
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice